Minerva Neurosciences, Inc. (NERV)
Company Description
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases.
Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.
The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia.
Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Country | United States |
Founded | 2007 |
IPO Date | Jul 1, 2014 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 9 |
CEO | Dr. Remy Luthringer Ph.D. |
Contact Details
Address: 1601 Trapelo Road, Suite 286 Waltham, Massachusetts 02451 United States | |
Phone | 617-600-7373 |
Website | minervaneurosciences.com |
Stock Details
Ticker Symbol | NERV |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001598646 |
CUSIP Number | 603380205 |
ISIN Number | US6033802058 |
Employer ID | 26-0784194 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Remy Luthringer Ph.D. | Executive Chairman and Chief Executive Officer |
Geoffrey Robin Race F.C.M.A., M.B.A. | President |
Frederick W. Ahlholm CPA | Senior Vice President, Chief Financial Officer and Secretary |
Joseph Reilly | Senior Vice President and Chief Operating Officer |
William B. Boni | Vice President of Investor Relations and Corporate Communications |
Prof. Michael Davidson M.D. | Chief Medical Officer |
Dr. Ramana Kuchibhatla Ph.D. | Senior Vice President and Head of Research and Development |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Feb 27, 2024 | 8-K | Current Report |
Feb 26, 2024 | 10-K/A | [Amend] Annual report |
Feb 22, 2024 | 10-K | Annual Report |
Feb 9, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Jan 18, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Nov 7, 2023 | 10-Q | Quarterly Report |
Sep 28, 2023 | 8-K | Current Report |
Aug 15, 2023 | ARS | Filing |
Aug 15, 2023 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Aug 15, 2023 | DEF 14A | Other definitive proxy statements |